Scarica l'app Stockscreener
10.61
0.00%
0.07
Precedente Chiudi:
$10.54
Aprire:
$10.71
Volume 24 ore:
14,115
Relative Volume:
0.06
Capitalizzazione di mercato:
$347.42M
Reddito:
$65.42M
Utile/perdita netta:
$-32.96M
Rapporto P/E:
-8.3543
EPS:
-1.27
Flusso di cassa netto:
$-19.87M
1 W Prestazione:
+1.93%
1M Prestazione:
-12.31%
6M Prestazione:
+75.67%
1 anno Prestazione:
-24.71%
Intervallo 1D:
$10.43
$10.96
Intervallo di 1 settimana:
$10.02
$10.96
Portata 52W:
$5.45
$15.11
Neuropace Inc Stock (NPCE) Company Profile
Nome
Neuropace Inc
Settore
Industria
Telefono
(650) 237-2700
Indirizzo
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Confronta NPCE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.61 | 347.42M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
131.46 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.08 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.42 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.00 | 104.24B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.23 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-21 | Iniziato | UBS | Buy |
| 2024-03-14 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Iniziato | Leerink Partners | Outperform |
| 2023-11-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Iniziato | Lake Street | Buy |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Iniziato | Robert W. Baird | Outperform |
| 2021-05-17 | Iniziato | JP Morgan | Overweight |
| 2021-05-17 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-17 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Neuropace Inc Borsa (NPCE) Ultime notizie
NeuroPace, Inc. (NASDAQ:NPCE) Short Interest Up 45.8% in March - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - MarketScreener
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Breakthrough: New Epilepsy Device Shows 82% Seizure Reduction, FDA Study Reveals - Stock Titan
Q1 Earnings Estimate for NeuroPace Issued By Leerink Partnrs - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Sees Large Growth in Short Interest - MarketBeat
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting - The Manila Times
Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes - Stock Titan
NeuroPace Announces Refocusing of Product Portfolio - The Manila Times
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance - MSN
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook By Investing.com - Investing.com Canada
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed - MarketScreener
NeuroPace to terminate distribution relationship for Seeg products - TipRanks
NeuroPace Shifts Focus to Core RNS System - TipRanks
Neuropace Inc Maintaining 2025 Revenue Guidance - MarketScreener
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook - Investing.com
NeuroPace Strategic Pivot: Higher Margins, AI Innovation, and 20% Growth Target Ahead - Stock Titan
NeuroPace (NASDAQ:NPCE) Shares Down 4.3%Should You Sell? - MarketBeat
Where are the Opportunities in (NPCE) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $328,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% – What’s Next? - Defense World
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
NeuroPace Leadership Reveals Growth Strategy: Key Insights Coming at Needham Conference - Stock Titan
(NPCE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Seed Treatment Market Top PlayersNeuropace, Inc., Biotronik, - openPR
Cantor Fitzgerald maintains Overweight on NeuroPace stock By Investing.com - Investing.com Australia
NeuroPace at attractive entry point, remains best idea, says Cantor Fitzgerald - TipRanks
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market By Investing.com - Investing.com Australia
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market - Investing.com India
Neuropace Inc Azioni (NPCE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neuropace Inc Azioni (NPCE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.85%
0.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):